RegeneRx Receives Notice of Allowance For U.S. Patent For Healing and Reversing Heart and Coronary Vessel Damage After A Heart Attack with TB4
RegeneRx Biopharmaceuticals Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”) today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue to heal and reverse heart and coronary vessel damage due to a heart attack, as well as to enhance the transition of immature heart cells into mature cells, among others.
Significant damage can be caused to the heart and coronary vessels after an ischemic event (lack of oxygen to cardiovascular tissues), during the opening of a vessel to restore blood flow (restenosis), or through cardiovascular surgeries. TB4 has been shown in numerous scientific publications to prevent, reduce and/or repair such damage. The subject patent will expire in 2022, not including any extensions that may be forthcoming due to the significant length of time required to obtain the patent.
“This patent will be an important addition to our cardiac intellectual property portfolio,” said J.J. Finkelstein, RegeneRx’s president and chief executive officer. “Our proprietary technology will be further protected, validating the substantial effort to secure it and supporting the value proposition to potential strategic partners that may be interested in working with us to develop RGN-352 for the reduction of damage associated with cardiovascular events.”
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products. RGN-259, the Company’s TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx’s clinical development efforts in the U.S through its joint venture, ReGenTree. RegeneRx was recently allowed by the FDA to move into phase 3 clinical trials with RGN-259 for the treatment of patients with NK. RGN-352, the Company’s TB4-based injectable drug candidate, is a phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar injuries. For additional information about RegeneRx please visit www.regenerx.com.
Forward-Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can be no assurance that any issued patents or licenses held by the Company or patent applications filed by the Company in the U.S. or any other country will result in future value. There can also be no assurance that any of the Company’s drug candidates will result in any approved products in the U.S. or any other country. Please view these and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the annual report on Form 10-K for the year ended December 31, 2014, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.